NL nr 3-2019_300 dpi

More documents

Recommendations

Info

BUSINESS INTERVIEW NanoZolid enables the controlled, long-term and personalized release of drugs for up to six months
The last few months have been very eventful for LIDDS; the last patient has been enrolled in their localized treatment of prostate cancer study and they are evaluating a possible listing on Nasdaq Stockholm’s Main Market. The CEO of LIDDS, Monica Wallter, gives us an update. TEXT b y M A L I N O T M A N I hat’s next for LIDDS and what results can we expect during 2019? “LIDDS will report the Phase IIb study very soon. Also, the Phase I study where solid tumors are injected with NanoZolid combined with docetaxel is ongoing and the first patient is treated. We have a preclinical program ongoing with STING agonists and additionally have very interesting other immune-oncology projects in the feasibility stage. Other highlights this year include the hiring of Charlotta Gauffin as Head of Clinical Development, and Markus Thor as Head of Business Development. We have also been invited to present the possibilities with the NanoZolid technology at recent conferences. Associate Professor Niklas Axén, Inventor and Head of Technology and Patents, attended the Pharma R&D Conference in Paris in March, and Stefan Grudén, Director of Pharmaceutical R&D, presented at the Formulation & Drug Delivery Congress in London in April.” What are your hopes and expectations for the future? “That LIDDS will be able to out license the clinical projects in prostate cancer and local cytostatic treatment of solid tumors after results are available. Additionally, that new projects will enter into clinical stage in the coming years.” You are evaluating a possible listing, what are the advantages? “A listing on Nasdaq Stockholm’s Main Market is a natural next step in the company’s development. Hopefully it will contribute to increased interest from a broader investor base as well as increased visibility, both in Sweden and globally.” In April, you initiated a novel TLR9 agonist project and announced a plan for a phase I clinical trial. Tell me more? “The NanoZolid technology addresses key issues in developing TLR agonists, as repeated intratumoral injections are needed using standard formulations. We will be focusing our project on TLR9, one of the most promising targets for increasing response and reversing resistance to immunotherapies. TLR9 agonists have been shown to be most effective when injected directly into a tumor. A preclinical program is ongoing to broaden the results obtained to date and we are now preparing for a Phase I clinical trial using NanoZolid combined with a TLR9 agonist. The first human study is planned to commence in 2020. There is significant commercial potential in this area of research and drug development and the market for TLR agonists is expected to be worth hundreds of millions of dollars over the coming years.” NLS Monica Wallter FACTS NANOZOLID LIDDS AB develops injectable drugs for cancer and other diseases based on a NanoZolid technology. NanoZolid helps solve some of the main problems with the way drugs work in the body and which affect patient quality of life. NanoZolid enables the controlled, long-term and personalized release of drugs for up to six months. NanoZolid can be combined with traditional small molecules, as well as with larger molecules. In March this year the United States Patent and Trademark Office issued a Notice of Allowance for the NanoZolid technology patent. The same patent was approved by the European Patent Office in 2018. With this new US patent, the NanoZolid technology will be protected until 2037 in both Europe and the US. NORDICLIFESCIENCE.ORG 17
Page 1 and 2: 169 SEK / 20 EUR / 25 USD IN FOCUS
Page 3 and 4: HELPING YOU SOLVE YOUR IP PUZZLE We
Page 5 and 6: Your Nordic Partner Within Life Sci
Page 7 and 8: Pharmaceutical Refrigerators Pharma
Page 9 and 10: TEXT b y M A L I N O T M A N I SARA
Page 11 and 12: TOP STORIES FINANCING ULTIMOVACS EN
Page 13 and 14: Your Preferred Partner in Europe In
Page 15: More than 25 years of experience
Page 19: PHASE I/IIA NEW CLINICAL DATA FROM
Page 24 and 25: ADVERTORIAL BUSINESS PRESENTATION R
Page 26: 26 NORDIC LIFE SCIENCE
Page 29 and 30: Eugen Steiner has for example serve
Page 31 and 32: ”När människor tänker på ”f
Page 33 and 34: To help their portfolio companies g
Page 35 and 36: hat kind of companies are you and y
Page 37 and 38: | Your molecule Our mission Drug su
Page 39 and 40: PHOTO MARGARETA BLOM SANDBAECK Jona
Page 41 and 42: What are some of your basic criteri
Page 43 and 44: Are Your Western Blots Constant Or
Page 45 and 46: ADVERTORIAL POTTER CLARKSON house
Page 47 and 48: FINANCING LIFE SCIENCE EXAMPLE NEW
Page 50 and 51: 50
Page 52 and 53: 52 Ann Rose, CEO Regulatory, ViCro
Page 54 and 55: 54 Barbro Ehnbom, the Founder and C
Page 56 and 57: ADVERTORIAL UNITED HEALTH FINLAND L
Page 58 and 59: TRONDHEIM Cilia in the nose of a ze
Page 60 and 61: SCIENCE REPORT RESEARCH NEWS FROM T
Page 62 and 63: 62 NORDICLIFESCIENCE.ORG
Page 64 and 65: PHOTO AKSEL K.HENRIKEN Ashley Mulle
Page 66 and 67:
YOUR KEY TO PROCESS DEVELOPMENT AND
Page 68 and 69:
SCIENCE YOUNG TALENT CEMRE MANAV PE
Page 70 and 71:
SCIENCE YOUNG TALENT
Page 72 and 73:
SCIENCE YOUNG TALENT Kaja Plucinska
Page 74 and 75:
SCIENCE YOUNG TALENT
Page 76 and 77:
HAEMOLYSIS FREE BLOOD PUMPING! GRAV
Page 78 and 79:
A QUARTET WITH A
Page 80 and 81:
The long-term goal for Cerenion is
Page 82 and 83:
, Founding a company of course teac
Page 84:
84 NORDIC LIFE SCIENCE
Page 87 and 88:
S T O C K H O L M G O T H E N B U R
Page 89 and 90:
Complyit We are consultants in Life
Page 91 and 92:
91
Page 93 and 94:
photochemical internalization (PCI)
Page 95 and 96:
Delivering Tomorrow’s Medicines
Page 97 and 98:
DENMARK Casper Slots and Martin Bon
Page 99 and 100:
- Odense
Page 101 and 102:
- Specialists in early clinical tri
Page 103:
GROWING UP IN AN ACADEMIC ENVIRONME
Page 106 and 107:
A FACE-TO-FACE INDUSTRY One of the
Page 108 and 109:
NLS INSIGHT LEGAL ADVICE
Page 110 and 111:
Swedish company Xbrane expects to l
Page 112 and 113:
Martin Åmark, CEO, Xbrane Biopharm
Page 114 and 115:
CAREERS INTERVIEW Anna-Leena Saarel
Page 116 and 117:
safety reporting processes for that
Page 118 and 119:
CAREERS IN A NEW JOB THE LATEST CAR
Page 120 and 121:
COLUMN HELENA STRIGÅRD, CEO SWEDEN
Page 122 and 123:
SO IT’S OVER FOR ANOTHER YEAR - T
Page 124 and 125:
acked by Sweden- BIO’s Jonas Ekst
Page 126 and 127:
EVENT HIGHLIGHTS The Nordic countri
Page 128 and 129:
UPCOMING EVENTS NORDIC LIFE SCIENCE
Page 130 and 131:
UPCOMING EVENTS INNOHEALTH … Part
Page 132:
What science can do AstraZeneca is
show all

NL nr 3-2019_300 dpi

Create successful ePaper yourself

Delete template?

Save as template?